Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of small-molecule HSF1 amplifiers by high content screening in protection of cells from stress induced injury.

Biochemical and biophysical research communications·2009
Same author

Nanowire transformation by size-dependent cation exchange reactions.

Nano letters·2009
Same author

Effect of haishengsu as an adjunct therapy for patients with advanced renal cell cancer: a randomized and placebo-controlled clinical trial.

Journal of alternative and complementary medicine (New York, N.Y.)·2009
Same author

Identification of inhibitors of HSF1 functional activity by high-content target-based screening.

Journal of biomolecular screening·2009
Same author

Antitumor effects of targeting hTERT lentivirus-mediated RNA interference against KB cell lines.

Oncology research·2009
Same author

Characteristics of emissive spectrum and the removal of nitric oxide in N2/02/NO plasma with argon additive.

Journal of environmental sciences (China)·2009

Related Experiment Video

Updated: Dec 12, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.9K

Targeting CD73 to augment cancer immunotherapy.

Meejeon Roh1, Derek A Wainwright2, Jennifer D Wu3

  • 1Robert H. Lurie Comprehensive Cancer Center, Department of Medicine-Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

Current Opinion in Pharmacology
|August 11, 2020
PubMed
Summary

CD73 (ecto-5'-nucleotidase) is an immunoinhibitory protein fueling tumor growth by creating an immunosuppressive environment. Targeting CD73 offers a promising therapeutic strategy, especially when combined with other treatments.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.6K

Related Experiment Videos

Last Updated: Dec 12, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.9K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.6K

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • CD73 (ecto-5'-nucleotidase) is an immunoinhibitory protein crucial for tumor progression and metastasis.
  • It converts extracellular ATP to adenosine, suppressing immune responses.
  • Tumors exploit this adenosinergic mechanism to evade immune attack, creating an immunosuppressive tumor microenvironment.

Purpose of the Study:

  • To review the multifaceted roles of CD73 in tumor cells and the immune system.
  • To highlight CD73 as an emerging immune checkpoint and a therapeutic target.
  • To discuss the potential of CD73-targeted therapies, particularly in combination strategies.

Main Methods:

  • Literature review of CD73's function in cancer.
  • Analysis of CD73's role in immune evasion and tumor microenvironment modulation.
  • Evaluation of therapeutic strategies targeting CD73.

Main Results:

  • CD73 expression on cancer and host cells promotes tumor growth and metastasis.
  • The CD73-adenosine pathway sustains an immunosuppressive tumor microenvironment.
  • CD73 acts as a significant immune checkpoint in cancer.

Conclusions:

  • CD73 is a key player in tumor immune evasion and progression.
  • Targeting CD73 is a promising therapeutic avenue for cancer treatment.
  • Combination therapies involving CD73 inhibitors may enhance treatment efficacy, especially with conventional therapies or other immune checkpoint inhibitors.